Anaveon

Founded: 2017
CEO: Thaminda Ramanayake
Shareholding: 37.2%
Stage: Clinical
Employees: 17
Raised in Series B financing: CHF110m
Clinical trials: 1

Unless stated all financials at 30 June 2026.

Anaveon website

Anaveon is leveraging its extensive expertise in protein engineering and immune cell targeting to advance ANV200 towards the clinic. ANV200 is a PD-1 targeting T-cell depleting antibody with potential application in several autoimmune diseases and the company is also building out an autoimmunity-focused pipeline behind it.

In parallel, Anaveon is finalising execution of its Phase I/II clinical trial for ANV600 in oncology, with Syncona continuing to believe in the anticipated clinical safety and efficacy of this programme. Anaveon will continue to seek paths to progress the molecule towards pivotal trials.

Anaveon has strengthened its leadership team with the appointments of Laetitia Pouzol as Chief Scientific Officer and Jill Jene as Chief Business Officer, to accelerate clinical development and pipeline expansion.

Best ideas Pre-clinical Clinical Late Clinical BLA

Anaveon

ANV600 — Range of solid tumours
ANV 200 – Autoimmune

Syncona team

Roel Bulthuis

Roel Bulthuis is an Executive Partner of Syncona Investment Management Limited He brings more than 20 years of life science venture capital, business development and investment banking experience. In his role at Syncona, Roel supports the investment team and works with portfolio companies, drawing on his significant experience and network across the sector. He is a Board member of Anaveon, iOnctur…

View Roel's biography

Position

Board member

Qualification

MSc, MBA

Gonzalo Garcia

Gonzalo is a Partner of Syncona Investment Management Limited. Gonzalo is a Director on the boards of Yellowstone Biosciences, Resolution Therapeutics and Anaveon. He was closely involved in the foundation of both Yellowstone and Resolution through hands-on membership of their founding leadership teams, covering both strategic and operational aspects of their set-up. Previously, Gonzalo was a Proj…

View Gonzalo's biography

Position

Board member

Qualification

PhD